Tarlaci 2009.

Methods	Single‐centre, randomised, parallel study: venlafaxine versus escitalopram
Participants	Country: Turkey Overall: N = 93 Sex: 17 M, 76 F (sex not reported for drop‐outs) Mean age: 31.4 ± 7.8 Diagnosis: migraine according to the criteria of the International Headache Society (ICHD‐II 2004) Exclusion criteria: abnormal systemic and neurological examination; < 3 migraine attacks per month; prophylactic medication for the last 2 months
Interventions	N = 35 venlafaxine ranging from 75 mg/day to 150 mg/day N = 58 escitalopram ranging from 10 mg/day to 20 mg/day
Outcomes	1. Number of attacks at 12 weeks 2. VAS 3. Duration at 12 weeks
Notes	12 drop‐outs from venlafaxine group due to adverse events Lost at follow‐up 22% (intention‐to‐treat analysis claimed but no further information)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information (randomised)
Allocation concealment (selection bias)	Unclear risk	No information
Blinding (performance bias and detection bias) All outcomes	Unclear risk	No information
Incomplete outcome data (attrition bias) All outcomes	High risk	Low drop‐out rate (11.4%) but unbalanced drop‐out in 1 group
Selective reporting (reporting bias)	Unclear risk	No information
Other bias	Unclear risk	Financial support not reported

CTTH: Chronic tension‐type headache

ETTH: Episodic tension‐type headache

PTI: Pain Total Index
 SD: standard deviation
 VAS: visual analogue scale